Digitalization + Life Sciences Tasly builds a new pattern of "dual ecology".

Founded in 1994, Tasly started with traditional Chinese medicine, and with the "small drop pill" to open up the situation of traditional Chinese medicine innovation and drifting to the sea, compound Danshen drop pill has become the first variety of Chinese patent medicine with annual sales exceeding 1 billion yuan. Nearly 30 years since its establishment and more than 20 years since it landed in the capital market, it is also the process of Tasly from a single product to a multi-format layout. At present, Tasly has gradually formed a product pattern of coordinated development of modern traditional Chinese medicine, biological drugs and chemical drugs, and has started a new journey of "dual ecology" pattern driven by digitalization and cutting-edge life science technology. As a representative enterprise of modernization and internationalization of traditional Chinese medicine, Tasly has broken the single ecology of "traditional Chinese medicine enterprise".

Tasly's new generation of high-speed pill dropping machine

To make modern Chinese medicine better and stronger

In the eighties and nineties of the last century, China's pharmaceutical industry began to flourish, Tasly was also born at this time, compound Danshen Dripping Pill was the main product of this enterprise at that time, with diligence and development, dream and passion, soon, Tasly people will build compound Danshen Dripping Pill into a "100 million" level variety, "small dripping pill" for a company to open up the situation.

Today, the company, which has been founded for 29 years and landed in the capital market for more than 20 years, has grown into a representative enterprise in the field of traditional Chinese medicine, and in the field of cardiovascular and cerebrovascular therapy, the company's traditional advantages, the core product Compound Danshen Dripping Pill ranks first in the cardiovascular and cerebrovascular Chinese patent medicine brand ranking of the terminal of China's public medical institutions. For the question of how to innovate traditional Chinese medicine, which is of general concern to the industry, Tasly gave its own answer: to do a good job in explaining the scientific connotation of traditional Chinese medicine; the use of clinical evaluation techniques of integrated traditional Chinese and Western medicine to evaluate traditional Chinese medicines; Through intelligent manufacturing, the transformation and upgrading of traditional Chinese medicine manufacturing is realized.

To this end, Tasly has built a digital intelligence precision R&D system with the research institute as the leader and the three major therapeutic areas as the focus, so that modern Chinese medicine can achieve component innovation and source innovation with the help of big data and AI. Recently, Tasly cooperated with HUAWEI CLOUD Pangu Model to jointly build a vertical model in the field of traditional Chinese medicine, build a new paradigm of traditional Chinese medicine research and development, and help Tasly continue to maintain its leading position in research and development.

In terms of product manufacturing, after several iterations, Tasly's intelligent manufacturing level has been greatly improved in terms of cost control and production efficiency. The company has developed a high-speed pill dropping machine with independent intellectual property rights, which is 25 times faster than the traditional pill dropping machine in the industry, and the production capacity is increased by 4 times, realizing a leapfrog improvement in production efficiency.

In response to changes in the industry, Tasly focuses on the "second echelon" created by the launch of new drugs and secondary development, and the "technical equipment" of excellence and continuous iteration. In 2019, the innovative Chinese medicine Paeonia Antispasmodic Granules was approved for marketing; In 2020, the supplementary application for the new indication of Qi Shen Yiqi Dripping Pill and the new indication of nourishing serum brain was approved for clinical trial; In 2021, the traditional Chinese medicine Kunxinning Granules, which was developed based on a global perspective, was approved for marketing; In the same year, the new diabetic retinopathy of Compound Danshen Dripping Pill was approved. Market analysis believes that the base of diabetic retinopathy patients is large, and the new indications of compound Danshen Dripping Pill are expected to obtain a broader new market space.

According to the just-released third quarter report of Tasly, the company achieved a year-on-year increase of 10.61% in the pharmaceutical industry in the first three quarters. The modern Chinese medicine sector, a long-term competitive advantage area, continued to grow steadily with a revenue growth rate of 16.72%. By the end of 2022, Tasly has a total of 26 R&D pipelines in the field of modern Chinese medicine, with intensive layout of phase II and IIII products, among which, phase III research is being carried out on Class 1 innovative Chinese medicine Anshen Dripping Pill and Spinal Pain Ning Tablets, and Phase II data summary has been completed for Gukang Granules, Tangerine Milk Fetish Ning Capsules, Susu Pediatric Cough Granules, Lianxia Xiaoyu Granules, and Sanhuang Eye Vision.

A few days ago, the National Modern Chinese Medicine Innovation Center initiated by Tianjin University of Traditional Chinese Medicine, Tasly Pharmaceutical Group and other 6 advantageous units in the field of traditional Chinese medicine was approved to be established, which is the only national manufacturing innovation center in the field of modern Chinese medicine layout and construction of the Ministry of Industry and Information Technology, Tasly will play a role in the national promotion of the high-quality development process of modern Chinese medicine industry with its platform advantages in the precision research and development of modern Chinese medicine and intelligent manufacturing.

Modern Chinese medicine, biological medicine, and chemical medicine "three arrows at the same time"

As early as more than 20 years ago, Yan Xijun, the founder of Tasly, was keenly aware that under the great changes in the survival rules of the industry, the situation of single products in the world would become a bottleneck, and decisively proposed: Tasly should advance into the field of chemical drugs and biological drugs.

Under the guidance of this strategy, Tasly has made great gains in the field of chemical drugs in recent years, and many drugs such as tadalafil, gefitinib tablets, and minodronic acid tablets have obtained registration approvals. In the national centralized procurement of drugs, Tasly's products such as temozolomide for injection and memantine hydrochloride sustained-release capsules won the bid. Approved in 2011, Puyuc, a new biological class 1 drug, is also the only recombinant human urokinase product on the market in China so far.

Under the leadership of Yan Kaijing, the new chairman of the board of directors of Tasly Holding Group, Tasly has accelerated the innovative R&D layout of modern traditional Chinese medicine, biological drugs and chemical drugs, formed a "four-in-one" R&D model of independent R&D, cooperative R&D, product introduction, and preferential licensing rights in the investment market, integrated global cutting-edge technologies, laid out leading targets, and efficiently transformed them into product cluster portfolios. In 2018, Tasly began to lay out regenerative medicine and build an international industrial platform for cell therapy. In 2021, Tasly introduced cutting-edge technologies such as high-intensity focused ultrasound ablation to promote its application in the treatment of prostate diseases, tumors and other fields. At the same time, Tasly has built a 4D integrated solution around the prevention and treatment of major diseases.

Nowadays, whether it is the place of forward-looking cutting-edge technology, the "four-in-one" R&D model, the full situation of modern traditional Chinese medicine, biological drugs and chemical drugs, or the reserve of nearly 100 R&D pipelines and a deeper international layout, it seems that it is difficult for Tasly to be defined as a "traditional Chinese medicine enterprise".

At the same time, the company has embarked on a new journey of digitalization and cutting-edge life science technology-driven "dual ecology" pattern while developing modern traditional Chinese medicine, biological medicine and chemical medicine.

As Yan Kaijing said, Tasly is "striving to realize the corporate vision of 'co-construction and symbiosis, building a global health value ecology', and become a respected global, digital and diversified business model enterprise." (Shi Wen)

Review: Yu Zaozao

Editor-in-charge: Huo Yue

Editor: Hu Na